For those short on time:

https://www.nature.com/articles/s41556-021-00821-8.pdf

There is a growing literature about the relationship between

COVID-19 disease severity, ACE2 expression and interferon regulation1–

6. Given that ACE2 is known to promote recovery after

lung injury and that SARS-CoV-2 manipulates the host interferon

response46–48, the misregulation of these two pathways may play a

major role in enhancing the severity of COVID-19. Our data suggest

that BRD2 is central to this regulatory network and therefore

pharmacological targeting of BRD2 may be a promising therapeutic

strategy for the treatment of COVID-19: BRD2 inhibition could

both block viral entry, through ACE2 downregulation, and act as

an ‘emergency brake’ for misregulated patient immune responses to

COVID-19, via downregulation of ISGs.